Jessica Neely1, Susan Kim2. 1. University of California, San Francisco, 550 16th Street, San Francisco, CA, 94158, USA. 2. University of California, San Francisco, 550 16th Street, San Francisco, CA, 94158, USA. Susan.Kim@ucsf.edu.
Abstract
PURPOSE OF REVIEW: We seek to provide a summary of the recent advances in juvenile dermatomyositis (JDM) that are moving the field toward precision care and personalized medicine for this uncommon condition. RECENT FINDINGS: There has been a recent international focus on developing uniform classification, disease monitoring, and treatment for juvenile dermatomyositis. In addition, there has been a steady development of translational studies to determine the genetic determinants, transcriptomic profiles, and immune cell phenotypes in JDM. Recent work toward standardization of disease classification, monitoring, and assessments together with advances in science, technology, and computing will facilitate the advancement toward true precision and personalized medicine in juvenile dermatomyositis in the near future.
PURPOSE OF REVIEW: We seek to provide a summary of the recent advances in juvenile dermatomyositis (JDM) that are moving the field toward precision care and personalized medicine for this uncommon condition. RECENT FINDINGS: There has been a recent international focus on developing uniform classification, disease monitoring, and treatment for juvenile dermatomyositis. In addition, there has been a steady development of translational studies to determine the genetic determinants, transcriptomic profiles, and immune cell phenotypes in JDM. Recent work toward standardization of disease classification, monitoring, and assessments together with advances in science, technology, and computing will facilitate the advancement toward true precision and personalized medicine in juvenile dermatomyositis in the near future.
Entities:
Keywords:
Idiopathic inflammatory myopathies; Juvenile dermatomyositis; Precision medicine; Translational research
Authors: Allison A Throm; Joshua B Alinger; Jeanette T Pingel; Allyssa L Daugherty; Lauren M Pachman; Anthony R French Journal: JCI Insight Date: 2018-11-15
Authors: Sara Sabbagh; Iago Pinal-Fernandez; Lisa G Rider; Andrew Lee Mammen; Takayuki Kishi; Ira N Targoff; Frederick W Miller Journal: Ann Rheum Dis Date: 2019-04-24 Impact factor: 19.103
Authors: Sarah Ringold; Peter A Nigrovic; Brian M Feldman; George A Tomlinson; Emily von Scheven; Carol A Wallace; Adam M Huber; Laura E Schanberg; Suzanne C Li; Pamela F Weiss; Robert C Fuhlbrigge; Esi M Morgan; Yukiko Kimura Journal: Arthritis Rheumatol Date: 2018-03-31 Impact factor: 10.995
Authors: Liza J McCann; Jamie J Kirkham; Lucy R Wedderburn; Clarissa Pilkington; Adam M Huber; Angelo Ravelli; Duncan Appelbe; Paula R Williamson; Michael W Beresford Journal: Trials Date: 2015-06-12 Impact factor: 2.279
Authors: Judith Wienke; Felicitas Bellutti Enders; Johan Lim; Jorre S Mertens; Luuk L van den Hoogen; Camiel A Wijngaarde; Joo Guan Yeo; Alain Meyer; Henny G Otten; Ruth D E Fritsch-Stork; Sylvia S M Kamphuis; Esther P A H Hoppenreijs; Wineke Armbrust; J Merlijn van den Berg; Petra C E Hissink Muller; Janneke Tekstra; Jessica E Hoogendijk; Claire T Deakin; Wilco de Jager; Joël A G van Roon; W Ludo van der Pol; Kiran Nistala; Clarissa Pilkington; Marianne de Visser; Thaschawee Arkachaisri; Timothy R D J Radstake; Anneke J van der Kooi; Stefan Nierkens; Lucy R Wedderburn; Annet van Royen-Kerkhof; Femke van Wijk Journal: Arthritis Rheumatol Date: 2019-03-12 Impact factor: 10.995
Authors: Felicitas Bellutti Enders; Brigitte Bader-Meunier; Eileen Baildam; Tamas Constantin; Pavla Dolezalova; Brian M Feldman; Pekka Lahdenne; Bo Magnusson; Kiran Nistala; Seza Ozen; Clarissa Pilkington; Angelo Ravelli; Ricardo Russo; Yosef Uziel; Marco van Brussel; Janjaap van der Net; Sebastiaan Vastert; Lucy R Wedderburn; Nicolaas Wulffraat; Liza J McCann; Annet van Royen-Kerkhof Journal: Ann Rheum Dis Date: 2016-08-11 Impact factor: 19.103